Campbell & CO Investment Adviser LLC Invests $2.31 Million in Catalyst Pharmaceuticals, Inc. $CPRX

Key Points

• Campbell & CO Investment Adviser LLC acquired 95,079 shares of Catalyst Pharmaceuticals valued at approximately $2.3 million, representing about 0.08% ownership in the company.
• Insider trading was reported with Preethi Sundaram selling 2,324 shares at an average price of $26.41, decreasing their ownership by 5.16%.
• Catalyst Pharmaceuticals saw analysts' ratings shift, with Zacks Research lowering its rating to "hold," while Cantor Fitzgerald upgraded it to "strong-buy," reflecting varied market confidence.

Campbell & CO Investment Adviser LLC acquired a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 95,079 shares of the biopharmaceutical company's stock, valued at approximately $2,306,000. Campbell & CO Investment Adviser LLC owned about 0.08% of Catalyst Pharmaceuticals at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of CPRX. Park Square Financial Group LLC acquired a new position in Catalyst Pharmaceuticals in the fourth quarter valued at approximately $29,000. Sound Income Strategies LLC acquired a new position in Catalyst Pharmaceuticals in the first quarter valued at approximately $64,000. GAMMA Investing LLC lifted its holdings in Catalyst Pharmaceuticals by 26.2% in the first quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company's stock valued at $68,000 after buying an additional 579 shares during the period. Quarry LP acquired a new position in Catalyst Pharmaceuticals in the fourth quarter valued at approximately $104,000. Finally, PNC Financial Services Group Inc. lifted its holdings in Catalyst Pharmaceuticals by 57.2% in the first quarter. PNC Financial Services Group Inc. now owns 5,501 shares of the biopharmaceutical company's stock valued at $133,000 after buying an additional 2,002 shares during the period. 79.22% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. Cantor Fitzgerald upgraded shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Thursday, June 5th. Wall Street Zen lowered shares of Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Saturday, August 9th. Finally, Zacks Research lowered shares of Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 19th. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, Catalyst Pharmaceuticals has a consensus rating of "Buy" and a consensus target price of $33.20.

Catalyst Pharmaceuticals Stock Up 0.9%

Shares of NASDAQ:CPRX traded up $0.19 during midday trading on Thursday, reaching $20.38. 1,085,606 shares of the company were exchanged, compared to its average volume of 1,313,928. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $19.00 and a fifty-two week high of $26.58. The stock has a fifty day simple moving average of $21.11 and a two-hundred day simple moving average of $22.55. The firm has a market cap of $2.49 billion, a PE ratio of 12.35, a P/E/G ratio of 0.81 and a beta of 0.70.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other news, CEO Richard J. Daly sold 22,970 shares of Catalyst Pharmaceuticals stock in a transaction dated Tuesday, August 26th. The shares were sold at an average price of $20.62, for a total value of $473,641.40. Following the completion of the transaction, the chief executive officer owned 226,794 shares of the company's stock, valued at $4,676,492.28. This trade represents a 9.20% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Preethi Sundaram sold 1,600 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $26.42, for a total transaction of $42,272.00. Following the completion of the transaction, the insider directly owned 41,081 shares of the company's stock, valued at approximately $1,085,360.02. This trade represents a 3.75% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 167,894 shares of company stock valued at $3,434,690 over the last quarter. 10.40% of the stock is currently owned by corporate insiders.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.